VENUSREM

Venus Remedies Share Price

 
Stock Hit Upper Circuit

 

Start SIP in VENUSREM

Start SIP
Venus Remedies live price: ₹878.45. It opened at ₹888 vs previous close ₹866; intraday high/low: ₹910/₹872. The 50 & 200 DMA stand at ₹777.28/₹624.19.

Venus Remedies Performance

  • Today's Low
  • ₹872
  • Today's High
  • ₹910
  • 52 Week Low
  • ₹278
  • 52 Week High
  • ₹945
  • Open Price₹888
  • Previous Close₹866
  • Volume56,356
  • 50 DMA₹777.28
  • 100 DMA₹718.42
  • 200 DMA₹624.19

Investment Returns

  • Over 1 Month + 23.73%
  • Over 3 Month + 9.58%
  • Over 6 Month + 95.28%
  • Over 1 Year + 195.18%

Smart Investing Starts Here Start SIP with Venus Remedies for Steady Growth!

Invest Now

Venus Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 15.4
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 1,174
  • P/B Ratio
  • 1.9
  • Average True Range
  • 49.65
  • EPS
  • 57.09
  • Dividend Yield
  • 0
  • MACD Signal
  • 31.1
  • RSI
  • 58.16
  • MFI
  • 74.8

Venus Remedies Financials

Venus Remedies Technicals

EMA & SMA

Current Price
₹878.45
+ 12.2 (1.41%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹821.76
  • 50 Day
  • ₹777.28
  • 100 Day
  • ₹718.42
  • 200 Day
  • ₹624.19

Resistance and Support

850.57 Pivot Speed
  • R3 928.98
  • R2 897.62
  • R1 881.93
  • S1 834.88
  • S2 803.52
  • S3 787.83

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Venus Remedies has an operating revenue of Rs. 699.88 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 38% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 97 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venus Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-29 Quarterly Results & Others To consider other business matters.
2025-11-10 Quarterly Results
2025-08-01 Quarterly Results
2025-07-08 Others Inter-alia, to consider 1. Notice of 36th Annual General Meeting. 2. Boards Report for Financial Year 2024-2025. 3. Other business matters.
2025-05-26 Audited Results

Venus Remedies F&O

Venus Remedies Shareholding Pattern

41.76%
2.25%
45.16%
10.83%

Venus Remedies FAQs

Venus Remedies share price is ₹878 As on 25 March, 2026 | 16:19

The Market Cap of Venus Remedies is ₹1174.2 Cr As on 25 March, 2026 | 16:19

The P/E ratio of Venus Remedies is 15.4 As on 25 March, 2026 | 16:19

The PB ratio of Venus Remedies is 1.9 As on 25 March, 2026 | 16:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23